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An imbalance between oxidative stress and antioxidant capacity is thought to play an
important role in the pathogenesis of chronic obstructive pulmonary disease (COPD).
However, studies in regard to stable COPD patients and effect of zinc supplementation are
lacking. We investigated the effects of zinc picolinate supplementation on the oxidant
stress, and pulmonary function tests (PFTs) of patients with stable COPD. Thirty patients
with COPD, and 15 healthy non-smokers who were matched for age and sex were included
in the study. Their baseline spirometry, plasma malondialdehyde (MDA), superoxide
dismutase (SOD), catalase (CAT), and zinc levels were measured. All parameters were
repeated after 8 weeks of supplementation with 22mg of zinc picolinate daily. The mean
MDA levels in the COPD group at baseline were higher than controls (0.5170.15 vs
0.3970.15 nmol/mL, p ¼ 0.037), while SOD (0.1670.022 vs 0.2070.04U/mL, p ¼ 0.000),
CAT (14.7973.03 vs 17.3772.60 k/mL, p ¼ 0.008) and zinc levels (77.3374.29 vs
91.4573.95mg/dL, p ¼ 0.000) were lower in the patients compared to controls. Eight
weeks of zinc supplementation produced significant increase in mean SOD (p ¼ 0.029) and
zinc levels (po0.001). However, no significant change in mean MDA, CAT levels and forced
expiratory volume in one second (FEV1) (% predicted), and FEV1/FVC (%) parameters was
observed after zinc supplementation. The Pearson’s coefficients of correlation between
MDA, SOD, CAT, Zn levels and spirometric measurements were not significant on either day
1 nor 8 weeks of zinc supplementation.
In conclusion, the results indicate that zinc supplementation may have favorable effects
on oxidant–antioxidant balance in patients with COPD. The lack of an effect on PFT may beElsevier Ltd. All rights reserved.
2333 555; fax: +90 424 2388096.
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Antioxidant effect in COPD patients 841due to the short duration of the supplementation. Longer duration of zinc supplementation
may be necessary to see clinical benefit.
& 2008 Elsevier Ltd. All rights reserved.Introduction
An imbalance between oxidative stress and antioxidant
capacity is thought to play an important role in the
pathogenesis and progression of chronic obstructive pul-
monary disease (COPD).1 There is considerable evidence for
an increased oxidant burden in smokers, particularly in
smokers who develop COPD, as shown by increased markers
of oxidative stress in the airspace, breath condensate,
blood, and urine.2 The increased oxidant burden derives
from the fact that cigarette smoke, the main etiological
factor in the pathogenesis of COPD, contains an estimated
1014 radicals/puff and about 4700 chemicals that include
peroxynitrite, superoxide radical, and oxides of nitrogen.3
Oxidants, while causing direct injury to the airway epithelial
cells, also lead to increments in lung connective tissue
proteolysis by oxidative inactivation of antiproteases,
thereby playing an important role in the pathogenesis of
COPD.4
Trace elements play important roles in the oxidant/
antioxidant balance and they are thought to be involved
directly or indirectly in the pathogenesis of several
diseases.5,6 Copper, zinc, and iron are the trace elements
frequently studied with respect to the pathogenesis of
COPD. Free iron in the airspaces and the intracellular iron
content of alveolar macrophages are increased in COPD,7
and iron is known to promote the formation of hydroxyl
radicals.5 Copper and zinc are two important metals that are
involved in a variety of biochemical reactions as co-factors.
In the cytoplasm of eukaryotic cells, superoxide dismutase,
one of the antioxidants enzymes, contains zinc in its active
site.8 It has been previously reported that serum zinc
concentrations decrease in COPD patients, and this decrease
is more prominent in severe COPD.9 Moreover, a reduction of
zinc content in the lung has been observed when inflamma-
tion was induced in rats by inhalation of nitrogen dioxide.10
Study in an animal models has shown that zinc functions as
an antioxidant. Zn may function as a site-specific antiox-
idant by two mechanisms. Firstly, it competes with Fe and
Cu for binding to cell membranes and some proteins,
displacing these redox-active metals and making them more
available for binding to ferritin and metallothionein,
respectively. Secondly, Zn binds the sulfhydryl groups in
proteins, protecting them from oxidation. Zn status does not
directly control tissue peroxide levels but can protect
specific molecules against oxidative and peroxidative
damage.11
Despite the known biochemical properties of zinc as an
antioxidant, few studies have investigated the use of zinc in
the management of oxidative stress in humans.6 We are not
aware of any previous study that addressed the effect of
zinc on oxidative stress in COPD patients. Therefore, the
present study was planned to demonstrate the effect of zinc
supplementation on oxidant stress in COPD patients.
Secondary end point was to evaluate the effect of zincsupplementation on PFT parameters of patients with stable
COPD.Materials and methods
The Ethics Committe of Firat University Faculty of Medicine
reviewed and approved the protocol. All study subjects
signed informed consent after the nature of the study had
been fully explained prior to their participation.Patients
Thirty male patients with clinically stable, stage III COPD
participated in the study. The diagnosis of COPD was made
by a pulmonary disease physician based on following
criteria; previous smoking history (all were ex-smokers
who were not smoked for at least 3 months prior to the
study), and largely irreversible airways obstruction with
o15% improvement in baseline FEV1 in response to inhaled
b2 agonist. The clinical pulmonary condition of the patients
was stable, with no acute exacerbations of COPD in the
month prior to entry into the study. Patients had no other
concurrent pulmonary or systemic disease and no evidence
of upper or lower respiratory tract infection.
All COPD patients participating in the study were provided
with a standardized therapy including inhaled salmeterol/
formoterol, inhaled tiotropium bromide, oral theophylline,
inhaled fluticazone/budesonide.
Thirty COPD patients participating in the study were
randomly divided into two groups. Fifteen patients received
oral placebo capsules and 15 patients received zinc capsules
(22mg zinc as zinc picolinate daily) for 8 weeks in addition
to their standardized therapy. Zinc and placebo capsules
were supplied by Solgar, Leonia, NJ 07605, USAControl subjects
Fifteen healthy non-smoker male subjects who were
matched for age recruited from the general population
participated in the study. No subject was receiving inhaled
bronchodilators, corticosteroids or any other medications.
None of them had a history of systemic or lung disease.Spirometry
The respiratory function tests were performed using a
spirometry device (Superspiro, Micromedical Limited, Ro-
chester, England). Maximal Expiratory Flow Volume curves
were obtained. Three acceptable and at least two repro-
ducible curves (the two highest FVC and FEV1 being within
200ml of each other) were obtained in each subject. The
highest values of FEV1 was selected for analysis.
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Blood was drawn at baseline and after 8 weeks of zinc
supplementation. Blood samples were centrifuged at 3000g
for 10min and sera were collected. Zinc was quantified using
a plasma aliquot diluted in distilled and de-ionized water.
The concentrations of zinc were determined by atomic
absorption spectrophotometry (Shimadzu AA-6701 spectro-
meter). An air/acetylene flame burner was used for
interpolating the concentration of zinc in the calibration
curve developed with standards in a glycerol–water mix-
ture.
Malondialdehyde (MDA), which is the end product of lipid
peroxidation, was measured spectrophotometrically as
described by Ohkawa.12 Total (Cu–Zn and Mn) SOD (EC
1.15.1.1) activity was determined according to the method
of Oyanagui.13 The CAT activity was determined by measur-Table 1 Demographic characteristics and PFT para-
meters of all COPD patients.
Parameter COPD
patients
treated with
Zn (n ¼ 15)
COPD patients
treated with
placebo
(n ¼ 15)
Age 61.0672.89 62.2673.19
Duration of disease
(years)
10.0672.21 11.4072.50
Smoking (pack/year) 54.7375.83 48.73721.50
FEV1 (% predicted) 42.7375.83 42.9374.80
FEV1/FVC (%) 64.2677.50 65.8675.93
Table 2 Comparison of mean plasma MDA, SOD, CAT, and Zinc
Parameter COPD patient
MDA levels, mean7SD (range) (nmol/mL) 0.5170.15
SOD levels, mean7SD (range) (U/mL) 0.1670.022
CAT levels, mean7SD (range) (k/mL) 14.7973.03
Zinc levels, mean7SD (range) (mg/dL) 77.3374.29
Significant p values.
Table 3 Effects of Zn supplementation (22mg/day) for 8 week
parameters.
Baseline val
MDA levels, mean7SD (range) (nmol/mL) 0.5570.16
SOD levels, mean7SD (range) (U/mL) 0.1670.02
CAT levels, mean7SD (range) (k/mL) 15.5073.79
Zinc levels, mean7SD (range) (mg/dL) 76.2974.22
FEV1 (% predicted) 42.7375.83
FEV1/FVC (%) 64.2677.50
ns, non-significant p values.
Significant p values.ing the decomposition of hydrogen peroxide at 240 nm,
according to the method of Aebi.14Statistical analysis
Data were analyzed using the statistical package for the
social sciences (SPSS) v12.0 software statistical program.
Results were given as group means7standard deviations
(SD). A p-value of o0.05 was considered statistically
significant. Paired t-tests were used to compare the
parameters of COPD group before and after zinc supple-
mentation. Pearson’s coefficient was used to determine
correlation between MDA, SOD, CAT, zinc levels and
spirometric measurements.Results
Table 1 shows the demographic characteristics and PFT
parameters of all COPD patients. No difference was
observed between COPD groups. Mean MDA level was higher
in COPD patients compared to healthy controls (po0.05).
However serum SOD, CAT, and zinc levels were lower in the
COPD group compared to the healthy control group (for all,
po0.05) (Table 2). Eight weeks of zinc supplementation was
associated with a significant increase in mean SOD
(p ¼ 0.029) and zinc levels (po0.001). However, no sig-
nificant change in mean MDA, CAT levels and FEV1 (%
predicted), and FEV1/FVC (%) parameters was observed
after zinc supplementation (Table 3). The Pearson’s coeffi-
cients of correlation between MDA, SOD, CAT, Zn levels and
spirometric measurements were not significant on either day
1 nor 8 weeks of zinc supplementation.levels in COPD patients and healthy controls.
s (n ¼ 30) Healthy controls (n ¼ 15) p Value
0.3970.15 0.037
0.2070.04 0.000
17.3772.60 0.008
91.4573.95 0.000
s on oxidant-antioxidant parameters and pulmonary function
ues After Zn supplementation p Value
0.4670.38 0.061ns
0.1870.015 0.029
16.2771.10 0.523ns
87.3674.96 o0.001
42.9372.71 0.898ns
64.0073.94 0.878ns
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In the present study, we have found that patients with COPD
have increased lipid peroxidation products, and decreased
antioxidants in plasma as compared to healthy controls. We
have observed that plasma MDA, SOD, CAT levels do not
correlate with FEV1 and zinc supplementation has no effect
on spirometric parameters.
Considerable evidence now links COPD with increased
oxidative stress and, therefore the status of antioxidant
defense mechanisms assumes paramount importance in this
disease. It is known that powerful oxidants are generated
during the inflammatory processes due to the activation of
neutrophils and thus markers of oxidative stress are
increased in systemic circulation.1 Previous studies have
reported evidence of oxidant-mediated injury in the air-
spaces, fluids, and serum of smokers and patients with
COPD.15–17 Increased lipid oxidation as well as alterations in
the antioxidant capacity have been found in the serum of
these subjects.18,19 Indeed, deficiencies in both enzymatic
and non-enzymatic antioxidant systems were described in
patients with COPD.20
MDA, an end product of lipid peroxidation, is used as a
marker of oxidative stress.21 Rahman et al.4 have demon-
strated that the products of lipid peroxidation increased and
antioxidant capacity decreased in COPD patients and in
smokers. MDA levels have been found to be increased in
COPD patients when compared to healthy controls.19,22,23 In
contrast, Karadag et al.9 showed similar concentrations of
MDA in COPD and control groups. They suggested that serum
MDA concentration may be normal in clinically stable COPD
patients as opposed to those with acute exacerbation. In
addition, the COPD patients enrolled in their study had not
smoked for at least 3 months and MDA is known to be closely
related to smoking. Our study found increased MDA
concentration in plasma of patients with stable COPD,
providing indirect evidence for increased production of
reactive oxygen species in these patients and hence more
lipid peroxidation. Although not significant, zinc supple-
mentation did show a trend in reducing plasma MDA levels
and a longer study may have made this change more
significant.
The alterations observed for both SOD and CAT activities
emphasize the redox imbalance in clinically stable patients.
Enhanced activities of these antioxidant enzymes have
also been demonstrated in alveolar macrophages from
young smokers.24 Daga et al.19 found that SOD levels were
30.9% lower in smokers compared to controls. In a similar
study, Kondo et al.25 found increased levels of oxygen
radical species and decreased levels of SOD in alveolar
macrophages from elderly chronic smokers. We also found
that the plasma levels of SOD and CATwere decreased in the
COPD group when compared to the healthy controls. This
may be due to increased production of free radicals in COPD
patients leading to increased consumption of antioxidant
enzymes.
The role of zinc in modulating oxidative stress has
recently been recognized. Zinc is known to induce the
production of metallothionein, which is very rich in cysteine
and is an excellent scavenger of OH radical.26 Recent studies
have shown that serum zinc concentrations in COPD patients
were lower than in control subjects. Furthermore, zinc wasfound to be lower in patients with severe (Grade III) COPD
compared to those with milder (Grade I and II) disease.9 We
also observed lower levels of zinc in COPD patients when
compared with healthy subjects. This might be secondary to
a decreased intake or an increased metabolism of zinc,
which might be due to activation of oxidant/antioxidant
systems in COPD.
Prasad et al.27 reported that zinc supplementation in
normal healthy subjects lowers the oxidative stress-related
marker MDA. The effects of zinc supplementation on
oxidative stress in subjects with type 2 diabetes mellitus
were recently evaluated. After 6 months of zinc supple-
mentation, plasma zinc increased, whereas the placebo
group showed no such changes.28 Moreover, it was reported
that zinc and antioxidants (vitamin C, vitamin E, and b-
carotene) significantly reduced the risk of developing
advanced age-related macular degeneration and prevented
blindness in a high-risk group of elderly subjects.29 To our
knowledge, there is no previous study which evaluated zinc
supplementation in COPD patients. We found that COPD
patients have decreased levels of zinc when compared with
healthy controls, and after zinc supplementation levels of
zinc increased significantly.
There are conflicting results in the literature regarding
the effect of antioxidant therapy on pulmonary functions.
Habib et al.30 found that addition of vitamin E to diet had no
effect on initial pulmonary functions. Daga et al.19 also
observed no significant improvement in pulmonary function
parameters (FEV1, FEV1/FVC, PEFR) after vitamin E supple-
mentation in COPD patients. Demir et al.31 treated patients
with an antioxidant preparation (5000 IU vitamin A, 250mg
vitamin C, 200 IU vitamin E, 7.5mg zinc, 1.0mg copper,
15.0mcg selenium, 1.5mg manganese) in addition to their
standard therapy. Their findings indicated that antioxidant
therapy as an adjunct to diet is effective on oxidant–antiox-
idant balance but has no demonstrable effect on PFT.
Although supplementation with a-tocopherol or b-carotene
for 5–8 year had no preventive effect on the development of
symptoms related to COPD,32 higher levels of antioxidant
nutrients were associated with better lung function in
NHANES 3.33 We observed that zinc supplementation over 8
weeks had no effect on spirometric parameters.
A limitation of our study was; all our COPD patients were
stage III, and had uniform lung function (FEV1% pre-
d ¼ 42.7375.83 in COPD group treated with Zn, FEV1%
pred ¼ 42.9374.80 in COPD group treated with placebo).
Given this lack of variation in lung function, it would be
difficult to correlate marker levels with FEV1. An other
limitation of our study is the duration of zinc supplementa-
tion. It is known that the major source of airways limita-
tion of COPD is in the small airways,34 as a result of small
airways disease (remodeling/fibrosis, etc.) and it has taken
many years of oxidative stress to get to this state. So,
expecting an improvement in FEV1 after an 8 weeks study
can be inadequate. If the duration of the study will be
longer, the effect of zinc on the pulmonary functions may be
appeared.
In conclusion, zinc supplementation may have favorable
effects on oxidant–antioxidant balance in patients with
COPD. However, the lack of an effect on PFT may be due to
the short duration of zinc supplementation in this study.
A large population-based cross-sectional study of longer
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antioxidant on pulmonary function in COPD patients.
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